UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2866-2875

2011

Volltextzugriff (PDF)

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

The New England journal of medicine, 2009-09, Vol.361 (10), p.947-957

2009

Volltextzugriff (PDF)

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

The Lancet (British edition), 2008-11, Vol.372 (9652), p.1809-1818

2008

Volltextzugriff (PDF)

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

Journal of clinical oncology, 2010-02, Vol.28 (5), p.744-752

2010

Volltextzugriff (PDF)

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042

2016

Volltextzugriff (PDF)

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Journal of clinical oncology, 2008-09, Vol.26 (26), p.4253-4260

2008

Volltextzugriff (PDF)

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

Journal of clinical oncology, 2009-05, Vol.27 (13), p.2253-2260

2009

Volltextzugriff (PDF)

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2021-09, Vol.385 (12), p.1091-1103

2021

Volltextzugriff (PDF)

Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin

Asia-Pacific journal of clinical oncology, 2007-06, Vol.3 (2), p.66-78

ARMOUR, Alison

2007

Volltextzugriff (PDF)

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

International journal of clinical oncology, 2015-12, Vol.20 (6), p.1102-1109

2015

Volltextzugriff (PDF)

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

The New England journal of medicine, 2021-09, Vol.385 (12), p.1091-1103

2021

Volltextzugriff (PDF)

Gefitinib plus docetaxel in non-small-cell lung cancer – Authors' reply

The Lancet (British edition), 2009, Vol.373 (9663), p.542-542

2009

Volltextzugriff (PDF)

Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study

American journal of respiratory and critical care medicine, 2008-06, Vol.177 (12), p.1348-1357

2008

Volltextzugriff (PDF)

Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1864-1871

2009

Volltextzugriff (PDF)

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1864-1871

2009

Volltextzugriff (PDF)

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

Journal of thoracic oncology, 2011-11, Vol.6 (11), p.1872-1880

2011

Volltextzugriff (PDF)

Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2576-2576

2017

Volltextzugriff (PDF)

Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5038-5038

2017

Volltextzugriff (PDF)

The Relationship Between Perceived Social Connectedness, Physical Wellbeing, and Subjective Aging in Older Adults

Armour, Alison

2017

Volltextzugriff (PDF)

PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.272-272

2018

Volltextzugriff (PDF)

Mental Illness: My Personal Experience, Our Professional Responsibility

Journal of midwifery & women's health, 2014-07, Vol.59 (4), p.470-470

2014

Volltextzugriff (PDF)

HLA-DRB1 07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.617-617

2015

Volltextzugriff (PDF)

Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.133-133

2015

Volltextzugriff (PDF)

Reply to D. Tassinari et al

Journal of clinical oncology, 2009-10, Vol.27 (28), p.e130-e131

2009

Volltextzugriff (PDF)

Mental illness: my personal experience, our professional responsibility

Journal of midwifery & women's health, 2014-07, Vol.59 (4), p.470-470

2014

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(55)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(25)
Female
(17)
Male
(11)
Aged
(10)
Middle Aged
(10)
Oncology
(10)
Biological And Medical Sciences
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)
Lung Neoplasms - Drug Therapy
(8)
Lung Neoplasms - Mortality
(8)
Medical Sciences
(8)
Chemotherapy
(7)
Quinazolines - Therapeutic Use
(7)
Adult
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Carcinoma, Non-Small-Cell Lung - Mortality
(6)
Quality Of Life
(6)
Quinazolines - Adverse Effects
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Gefitinib plus docetaxel in non-small-cell lung cancer – Authors' reply

Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study

Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456

Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

The Relationship Between Perceived Social Connectedness, Physical Wellbeing, and Subjective Aging in Older Adults

PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs

Mental Illness: My Personal Experience, Our Professional Responsibility

HLA-DRB1 07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO

Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx)

Reply to D. Tassinari et al

Mental illness: my personal experience, our professional responsibility

Suchergebnisse filtern